Girard Partners’s CRISPR Therapeutics CRSP Stock Holding History

Girard Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14	Closed	–	–	359
2018 Q3	$0	Buy	+14	New	+$733	﹤0.01%	945

Other funds holding CRSP

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Girard Partners's CRSP Position: Q4 2018 in Review

Girard Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2018, closing a stake of 14 shares.

Girard Partners first reported a position in CRSP in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 155 funds tracked by Wall St. Rank hold CRSP as of Q4 2018.

Girard Partners reported no remaining CRISPR Therapeutics position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 14 CRISPR Therapeutics shares in Q4 2018.
Girard Partners first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 1 quarter.
Girard Partners's CRISPR Therapeutics position peaked at $0 in Q3 2018.
155 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.